Lantheus Holdings, Inc. Reports 2016 Second Quarter Financial Results

NORTH BILLERICA, Mass.--  Lantheus Holdings, Inc. (the “Company”) (LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today reported financial results for its second quarter ended June 30, 2016.
 
The Company’s worldwide revenue for the second quarter of 2016 totaled $78.0 million, representing an increase of 6% as-reported compared to $73.3 million reported for the second quarter of 2015. Second quarter worldwide revenue results reflect continued strong sales of DEFINITY® and stable revenues from the nuclear products portfolio driven by contracts with key radiopharmacy customers.
Read more: Lantheus Holdings Inc ( LNTH )

CombiMatrix Corporation Reports Second Quarter 2016 Financial and Operating Results

Revenue growth, gross margin expansion and strong cash reimbursement support progress toward goal of profitability
Conference Call Begins Today at 4:30 p.m. Eastern Time
 
IRVINE, Calif., Aug. 03, 2016 -- CombiMatrix Corporation (CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, today reported financial results for the three and six months ended June 30, 2016, and provided a business update.
 
“During the second quarter we made excellent progress toward our goal of achieving profitability with revenue growth, expanded gross margin, improved cash collections and a narrowed operating loss,” said Mark McDonough, CombiMatrix President and CEO.  “Diagnostic services revenues grew 21%, driven by a 32% increase in reproductive health revenues reflecting increased average revenue per test for miscarriage analysis and prenatal testing.
Read more: CombiMatrix Corporation ( CBMX )

Check-Cap Announces Agreement with GE Healthcare for X-Ray Capsule Manufacturing Collaboration

ISFIYA, Israel and BOSTON, Aug. 4, 2016  -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced it has entered into an agreement with GE Healthcare to develop and validate high-volume manufacturing for X-ray source production and assembly into Check-Cap's capsule. Upon successful completion, the parties may discuss collaboration on execution of a high-volume manufacturing facility and distribution of the Check-Cap system.
 
"We are very excited to commence this strategic relationship with GE Healthcare as we continue our efforts to optimize the supply chain for the Check-Cap system," said Bill Densel, CEO of Check-Cap. "GE Healthcare is a global leader in the development, manufacturing, and distribution of diagnostic imaging agents and radio-pharmaceutical drugs and devices. We believe that leveraging their experience and expertise provides us with a significant opportunity to meet our goal of increasing the time and cost efficiencies of production of our capsule for use in future clinical trials and commercialization."
Read more: Check-Cap Ltd ( CHEK )

Psychemedics Corporation Announces Record Revenues And Earnings

ACTON, Mass., July 26, 2016 -- Psychemedics Corporation (PMD) today announced second quarter financial results for the period ended June 30, 2016.  The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of August 5, 2016 to be paid on August 15, 2016.  This will be the Company's 80th consecutive quarterly dividend.
 
The Company's revenue for the quarter ended June 30, 2016 was $9.7 million versus $7.0 million for the quarter ended June 30, 2015, an increase of 39%.  Net income for the quarter ended June 30, 2016 was $1.6 million or $0.30 per diluted share, versus $252 thousand or $0.05 per diluted share, for the comparable period last year, an increase of 547%. 
Read more: Psychemedics Corporation ( PMD )

Exact Sciences Completes 54,000 Cologuard Tests during the Second Quarter

MADISON, Wis., July 26, 2016 -- Exact Sciences Corp. (EXAS) today announced that the company generated revenues of $21.2 million during the second quarter ended June 30, 2016, representing a 161-percent increase from $8.1 million in the second quarter of 2015. The company completed approximately 54,000 Cologuard tests during the second quarter, an increase of approximately 160 percent compared to the 21,000 tests completed during the same period of 2015. Since Cologuard's launch and through the end of the second quarter of 2016, approximately 41,000 physicians have ordered the test.
 
"Continued execution of our sales and direct-to-consumer marketing strategies during the second quarter drove an increase in new physicians ordering Cologuard and broader patient awareness and demand for our non-invasive colon cancer screening test," said Kevin Conroy, chairman and CEO of Exact Sciences. "As a result, we delivered another strong quarterly financial performance, highlighted by robust annualized revenue growth, a sequential increase in completed tests that exceeded our expectations, and solid expense control and favorable cash utilization." 
Read more: Exact Sciences Corp ( EXAS )